Hairy cell leukemia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hairy cell leukemia}} | {{Hairy cell leukemia}} | ||
{{CMG}} | {{CMG}}; {{GRR}} {{Nat}} | ||
==Overview== | ==Overview== | ||
| Line 9: | Line 9: | ||
* Three immunotoxin drugs are in Phase II trials at the [[NIH]]'s [[National Cancer Institute]] in the U.S.: [[BL22]]<ref>{{ClinicalTrials|NCT00074048}}</ref>, HA22<ref>{{ClinicalTrials|NCT00462189}}</ref> and LMB-2.<ref>{{ClinicalTrials|NCT00337311}}</ref> | * Three immunotoxin drugs are in Phase II trials at the [[NIH]]'s [[National Cancer Institute]] in the U.S.: [[BL22]]<ref>{{ClinicalTrials|NCT00074048}}</ref>, HA22<ref>{{ClinicalTrials|NCT00462189}}</ref> and LMB-2.<ref>{{ClinicalTrials|NCT00337311}}</ref> | ||
* All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization. BL22 and HA22 attack a common protein called CD22, which is present on hairy cells and healthy B cells. LMB-2 attacks a protein called CD25, which is not present in HCL-variant, so LMB-2 is only useful for patients with HCL-classic or the Japanese variant. | * All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization. BL22 and HA22 attack a common protein called [[CD22]], which is present on hairy cells and healthy B cells. LMB-2 attacks a protein called [[CD25]], which is not present in HCL-variant, so LMB-2 is only useful for patients with HCL-classic or the Japanese variant. | ||
* All three of these therapies are available only at the National Cancer Institute in Bethesda, Maryland, USA. While initial results are generally favorable, it is likely to be a number of years before these drugs are available on the market. | * All three of these therapies are available only at the National Cancer Institute in Bethesda, Maryland, USA. While initial results are generally favorable, it is likely to be a number of years before these drugs are available on the market. | ||
Latest revision as of 17:23, 8 April 2019
|
Hairy cell leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hairy cell leukemia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hairy cell leukemia future or investigational therapies |
|
FDA on Hairy cell leukemia future or investigational therapies |
|
CDC on Hairy cell leukemia future or investigational therapies |
|
Hairy cell leukemia future or investigational therapies in the news |
|
Blogs on Hairy cell leukemia future or investigational therapies |
|
Risk calculators and risk factors for Hairy cell leukemia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Grammar Reviewer: Natalie Harpenau, B.S.[2]
Overview
Future or Investigational Therapies
- Three immunotoxin drugs are in Phase II trials at the NIH's National Cancer Institute in the U.S.: BL22[1], HA22[2] and LMB-2.[3]
- All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization. BL22 and HA22 attack a common protein called CD22, which is present on hairy cells and healthy B cells. LMB-2 attacks a protein called CD25, which is not present in HCL-variant, so LMB-2 is only useful for patients with HCL-classic or the Japanese variant.
- All three of these therapies are available only at the National Cancer Institute in Bethesda, Maryland, USA. While initial results are generally favorable, it is likely to be a number of years before these drugs are available on the market.